Sign In
Buy ATHE
$4.01
-0.0100 (-0.249%)
At Close: Jun 03, 2026
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
07:25am, Tuesday, 19'th May 2026
– Alterity's novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA –
– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports diagnosis and correlates with clinical severity in pat
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
07:25am, Thursday, 07'th May 2026
MELBOURNE, Australia and SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to deve
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
07:25am, Thursday, 30'th Apr 2026
Highlights Aligned with the FDA in two Positive Type C meetings supporting key elements of the planned Phase 3 program for ATH434 in MSA Advancing ATH434 toward pivotal Phase 3 program; on track for E
Alterity Therapeutics Limited (ATHE) Discusses Phase II Data and Development Strategy for ATH434 in Multiple System Atrophy Transcript
MELBOURNE, Australia and SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to de
- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale - - Effects seen on both daily function and neurological examination, consistent with previo
Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
07:25am, Friday, 17'th Apr 2026
MELBOURNE, Australia and SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to de
Head to Head Contrast: NovoCure (NASDAQ:NVCR) versus Alterity Therapeutics (NASDAQ:ATHE)
01:11am, Thursday, 16'th Apr 2026
NovoCure (NASDAQ: NVCR - Get Free Report) and Alterity Therapeutics (NASDAQ: ATHE - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two
Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Short Interest Up 139.4% in March
01:30am, Tuesday, 14'th Apr 2026
Alterity Therapeutics Limited - Sponsored ADR (NASDAQ: ATHE - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short inte
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
07:25am, Monday, 30'th Mar 2026
Alignment reached on key elements of ATH434 Phase 3 development program Alignment reached on key elements of ATH434 Phase 3 development program
Alterity Therapeutics Conference: ATH434 Phase II MSA Data, FDA Talks Next, Phase III Set
03:07am, Thursday, 26'th Mar 2026
Alterity Therapeutics (NASDAQ: ATHE) outlined its development strategy for lead drug candidate ATH434, highlighting positive Phase II data in multiple system atrophy (MSA), planned regulatory interact
Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Short Interest Up 69.4% in February
03:50am, Sunday, 15'th Mar 2026
Alterity Therapeutics Limited - Sponsored ADR (NASDAQ: ATHE - Get Free Report) saw a large growth in short interest during the month of February. As of February 27th, there was short interest totaling
Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit
07:25am, Monday, 09'th Mar 2026
MELBOURNE, Australia and SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to de
– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies –
